Integrative Oncology

Rethinking Cancer at the Root: The Mitochondrial–Stem Cell Connection and an Orthomolecular Approach to Treatment

INTEGRATIVE ONCOLOGY

By Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

Published by Yoon Hang Kim MD | Telemedicine across Iowa, Illinois, Missouri, Texas, Georgia & Florida

⚠ Medical Disclaimer

This article is intended for educational purposes only and does not constitute medical advice. The therapies discussed include investigational and off-label treatments that are not currently considered standard of care in oncology. Patients should never modify, discontinue, or supplement cancer treatment without guidance from their oncologist and a qualified integrative medicine physician. Some agents discussed carry real toxicity risks and should not be self-administered.

Introduction: Is Cancer a Metabolic Disease?

For decades, oncology has operated primarily from a genetic framework — the idea that cancer is, at its core, a disease of DNA mutations. Chemotherapy, targeted agents, and immunotherapy have all been built around this paradigm. And while they represent genuine progress, they share a common blind spot: they largely fail to address why some tumors recur, why metastasis is so difficult to prevent, and why certain cancer cells seem functionally immortal.

A growing body of research is now challenging this framework — not by dismissing genetics, but by asking a prior question: what goes wrong first?

A landmark 2024 paper published in the Journal of Orthomolecular Medicine by Baghli, Makis, Marik, and colleagues proposes a compelling answer. Their Mitochondrial–Stem Cell Connection (MSCC) theory argues that cancer may originate not from a random DNA mutation, but from chronic mitochondrial dysfunction in stem cells — and that this metabolic failure is what generates the cancer stem cells (CSCs) responsible for the most dangerous aspects of malignancy. A companion theoretical paper supporting the MSCC framework was published in a peer-reviewed journal and indexed in PubMed (PMID: 38668357).

This article breaks down the MSCC theory, explains the 7-step orthomolecular protocol proposed in the paper, and provides an honest clinical appraisal — distinguishing what is evidence-supported from what remains experimental.

The MSCC Theory: What It Proposes

The MSCC theory rests on three interconnected claims:

Mitochondria — not mutated DNA — are the primary initiating event in cancer development.
Specifically, chronic oxidative phosphorylation (OxPhos) failure in stem cells leads to metabolic reprogramming and the formation of cancer stem cells (CSCs).
These CSCs then drive tumor growth, treatment resistance, metastasis, and relapse — the outcomes that matter most clinically.

Key Concept: The Warburg Effect Revisited

Otto Warburg first observed in the 1920s that cancer cells preferentially use glycolysis (fermentation) even in the presence of oxygen — an inefficient but rapid energy strategy. The MSCC theory builds on this observation, arguing that Warburg metabolism is not an adaptation but a consequence: mitochondrial failure forces cells to revert to fermentable fuels (glucose and glutamine). The degree of malignancy, the authors argue, may correlate directly with the depth of mitochondrial dysfunction.

Why Cancer Stem Cells Are the Clinical Target That Matters

Conventional oncology treats bulk tumor cells — and often does so effectively in the short term. What standard therapies frequently miss are CSCs, the small subset of tumor cells that:

Self-renew indefinitely
Are inherently resistant to chemotherapy and radiation
Drive metastasis to distant sites
Are responsible for relapse after remission

This is not a fringe claim. A substantial body of peer-reviewed oncology literature has documented CSC resistance as a core problem in cancer biology. The MSCC protocol is specifically designed around this clinical reality — not treating what is visible in the tumor, but targeting the cells most likely to cause death.

The 7-Step Orthomolecular Protocol: Components and Clinical Commentary

The protocol is organized as a 'press–pulse' therapeutic strategy:

Press therapies: sustained metabolic stress (diet, fuel restriction, mitochondrial support)
Pulse therapies: intermittent high-impact interventions (pro-oxidant infusions, targeted drugs)

The goal is systemic metabolic weakening of cancer cells followed by selective destruction — a logic that mirrors how resistance-based cancer therapies are being reconsidered in conventional oncology.

Step	Goal	Tools	Mechanism	Clinical Status
Step 1 — Glucose Restriction	Suppress glycolysis	Ketogenic diet, intermittent fasting, metformin, 2-DG (experimental)	↓ blood glucose → metabolic stress on cancer cells	Keto + metformin: accepted adjuncts. 2-DG: investigational only.
Step 2 — Glutamine Targeting	Block secondary cancer fuel	Dietary restriction, EGCG, DON (experimental glutaminase inhibitor)	↓ glutaminolysis → ↓ TCA intermediates → ↓ tumor energy	EGCG: low risk, modest data. DON: toxic, not standard use.
Step 3 — OxPhos Restoration	Restore mitochondrial function	CoQ10, alpha-lipoic acid, B vitamins, magnesium, DCA (repurposed)	Enhance electron transport chain; DCA redirects pyruvate into mitochondria	Supplements: low-risk, limited effect size. DCA: controversial, neuropathy risk.
Step 4 — Pro-Oxidant Therapy	Exploit cancer's weaker antioxidant defenses	IV vitamin C (1.5 g/kg), artemisinin, HBOT	↑ ROS → selective cancer cell death	IVC: studied, mixed evidence. HBOT: niche use. Neither is standard of care.
Step 5 — CSC Targeting	Prevent recurrence and metastasis	Doxycycline, azithromycin, berberine, curcumin	Disrupt mitochondrial biogenesis in CSCs → impair self-renewal	Preclinical data exists. Antibiotic repurposing not guideline-based.
Step 6 — Anti-Angiogenesis	Limit tumor blood supply	Curcumin, resveratrol, EGCG	↓ VEGF signaling → ↓ tumor vascularization	Weaker than pharmaceutical anti-angiogenics. Useful as adjuncts.
Step 7 — Metabolic Optimization	Create an anti-cancer systemic environment	Exercise, weight loss, sleep, stress reduction	↓ insulin, ↓ systemic inflammation, ↑ mitochondrial health	Strongest evidence base. Should be foundational in every cancer care plan.

Step-by-Step Deep Dive

Step 1 — Reduce Glucose Availability

The rationale here is straightforward and well-supported: most cancer cells are hyperglycemic consumers. Reducing available glucose through a ketogenic diet, metabolic fasting, or the glucose-lowering effects of metformin creates a substrate disadvantage for cancer cells while normal cells adapt through fat oxidation.

Metformin has accumulated meaningful observational and retrospective data suggesting anti-cancer benefit, likely through AMPK activation and mTOR inhibition. It is among the most defensible adjunct agents in this protocol.

2-Deoxyglucose (2-DG): A synthetic glucose analogue that cannot be metabolized — it essentially 'jams' the glycolytic pathway. This remains investigational and should not be used outside clinical trial settings.

Step 2 — Target Glutamine

After glucose, glutamine is the second major fuel cancer cells exploit. It feeds both energy production (via the TCA cycle) and biosynthetic pathways for nucleotides and amino acids. Clinically, glutamine targeting is still in its early stages.

EGCG (epigallocatechin gallate): The primary bioactive polyphenol in green tea. It has demonstrated glutaminase inhibition in preclinical models and is low-risk as a dietary supplement.

DON (6-diazo-5-oxo-L-norleucine): A potent glutaminase inhibitor that showed early promise but was shelved due to significant GI toxicity. Modified derivatives are currently under investigation.

Step 3 — Restore Mitochondrial Function

This step sits at the philosophical heart of the MSCC protocol. If impaired OxPhos is the origin of cancer stem cell formation, then restoring mitochondrial function in non-cancerous cells — and disrupting it selectively in cancer cells — becomes a coherent therapeutic goal.

CoQ10: Essential cofactor in the mitochondrial electron transport chain. Oral supplementation is generally safe, commonly 100–400 mg/day.
Alpha-lipoic acid: Functions as both a mitochondrial cofactor and antioxidant. May have mild anti-tumor properties in preclinical models.
Dichloroacetate (DCA): Activates pyruvate dehydrogenase, pushing pyruvate into the mitochondria rather than glycolysis. Several small human studies exist. Peripheral neuropathy is the primary dose-limiting toxicity.

Step 4 — Pro-Oxidant Strategies

Normal cells can handle oxidative stress through robust antioxidant systems. Cancer cells — particularly those with already-dysfunctional mitochondria — are more vulnerable to ROS accumulation. This creates a therapeutic window that several integrative oncology agents try to exploit.

Intravenous Vitamin C: At pharmacologic doses (≥1.5 g/kg), IV ascorbate generates hydrogen peroxide in the tumor microenvironment, acting as a pro-oxidant rather than an antioxidant. Multiple pilot trials have examined IVC as an adjunct to standard chemotherapy. Data is encouraging but not definitive.

Artemisinin: A compound derived from sweet wormwood with documented anti-parasitic and preliminary anti-cancer activity in preclinical models. Mechanism involves iron-dependent ROS generation. Clinical data in oncology is limited.

Hyperbaric Oxygen Therapy (HBOT): Increases tissue oxygen tension, theoretically creating oxidative stress in hypoxic tumor microenvironments. Some early clinical data in glioblastoma and other cancers. Not standard of care.

Step 5 — Target Cancer Stem Cells Directly

This step includes some of the most intriguing — and most controversial — components of the protocol. The logic is compelling: if CSCs are mitochondria-dependent for their self-renewal machinery, then agents that specifically disrupt mitochondrial biogenesis in CSCs could prevent relapse.

Doxycycline and azithromycin: Antibiotics that inhibit mitochondrial protein synthesis (as mitochondria share evolutionary origins with bacteria). In vitro studies show preferential disruption of CSC mitochondrial function. Several published studies support this mechanism, though large-scale clinical validation is lacking.

Berberine: A plant alkaloid with broad metabolic effects including AMPK activation and mitochondrial disruption in cancer cells. Emerging clinical data in oncology is preliminary.

Curcumin: Extensively studied phytochemical with pleiotropic effects including NF-κB inhibition, anti-angiogenic activity, and CSC pathway disruption. Bioavailability limitations are a longstanding challenge; phospholipid-complexed formulations improve absorption.

Step 6 — Anti-Angiogenic Support

While pharmaceutical anti-angiogenics like bevacizumab are significantly more potent, the nutraceutical agents in this step (curcumin, resveratrol, EGCG) offer a reasonable low-risk adjunctive layer that may have complementary utility alongside conventional therapy.

Step 7 — Metabolic and Lifestyle Optimization

This is the most evidence-supported step in the entire protocol and arguably the one most underemphasized in standard oncology care. Hyperinsulinemia, visceral adiposity, chronic inflammation, sleep deprivation, and sedentary behavior are all well-established pro-tumorigenic factors. Addressing them is not alternative medicine — it is foundational preventive oncology.

Every patient with cancer — regardless of what else is being done — should be engaged in metabolic optimization as a core part of their care plan.

Critical Appraisal: Strengths and Limitations

Strengths of the MSCC Model

Addresses treatment resistance and relapse — the outcomes that actually kill patients — rather than focusing only on primary tumor reduction.
Aligns with decades of established cancer metabolism research, including the Warburg effect, mTOR biology, and mitochondrial regulation of apoptosis.
Multi-target approach reflects current thinking in precision oncology, which increasingly recognizes that single-agent strategies are insufficient.
Authors include credentialed researchers and clinicians with track records in orthomolecular medicine and metabolic oncology.

Limitations and Concerns

Important Clinical Context

No randomized controlled trials validate the full MSCC protocol. Evidence draws primarily from in vitro studies, animal models, and small clinical series.
Several proposed agents carry meaningful toxicity risk (DCA: neuropathy; DON: GI toxicity; high-dose IVC requires G6PD screening and renal monitoring).
The claim that mitochondrial dysfunction is the primary origin of cancer — rather than a contributing factor — remains debated in cancer biology.
Supplement-heavy protocols are vulnerable to pharmacokinetic failures: poor bioavailability, drug interactions, and dose-inconsistency across products.

Bottom line: The MSCC protocol is not a replacement for standard-of-care oncology. It is a thoughtful, mechanistically-grounded integrative framework that may offer adjunctive benefit when applied carefully by a knowledgeable clinician.

What Is Most Defensible Clinically — Right Now

For physicians and patients working in an integrative oncology context, the most evidence-supported elements from this protocol include:

Metabolic optimization: Weight management, physical activity, insulin control, sleep hygiene. Strong evidence. Low risk. Should be universal.
Metformin: Reasonable off-label adjunct in select patients with diabetes, pre-diabetes, or obesity-related cancers. Requires monitoring.
Low-risk mitochondrial support: CoQ10, alpha-lipoic acid, B vitamins, magnesium — as part of a comprehensive nutritional strategy.
IV Vitamin C: Available through trained integrative oncology practitioners. Most appropriate as an adjunct during conventional treatment, with appropriate screening (G6PD, renal function).
Curcumin and EGCG: Broad-spectrum, low-risk nutraceuticals with plausible mechanisms. Worth considering in a comprehensive integrative plan.
Doxycycline repurposing: An area worth watching — the preclinical data is compelling. Clinical use requires careful discussion and is not yet standard.

Conclusion: A Metabolic Lens on Cancer Care

The Mitochondrial–Stem Cell Connection theory does not claim to have solved cancer. What it offers is a more complete map of the terrain — one that explains why the disease so often escapes our best treatments and points toward targets we have largely ignored.

Whether or not every component of the proposed protocol eventually proves clinically effective, the underlying shift it represents is valuable: cancer is not just a genetic problem. It is a metabolic one. And addressing metabolism — through diet, mitochondrial support, fuel restriction, and systemic health optimization — belongs at the center of integrative cancer care, not the margins.

At Yoon Hang Kim MD, this kind of evidence-informed thinking — rigorous, nuanced, and patient-centered — is exactly the approach we bring to complex chronic illness, including integrative oncology support.

Interested in Integrative Oncology Support?

At Yoon Hang Kim MD, Dr. Yoon Hang Kim offers personalized, evidence-informed integrative medicine consultations — including integrative oncology support — via telemedicine for patients in Iowa, Illinois, Missouri, Texas, Georgia, and Florida.

Our membership-based model means you receive the time, attention, and individualized care that complex cases require. To learn more, visit our fee schedule or request a consultation.

References

1. Baghli I, Makis W, Marik PE, Gonzalez MJ, Grant WB, Hunninghake R, Levy TE, Lim H, Cheng RZ, Bondarenko I, Bousquet P, Ortiz R, Mary M, D'Agostino DP, Martinez P. Targeting the Mitochondrial–Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol. J Orthomolecular Med. 2024;39(3). Available at: https://isom.ca/article/targeting-the-mitochondrial-stem-cell-connection-in-cancer-treatment-a-hybrid-orthomolecular-protocol/

2. Baghli I, et al. Mitochondrial–Stem Cell Connection: Providing Additional Explanations for Understanding Cancer. [Published peer-reviewed companion paper]. PMID: 38668357

3. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314. PMID: 13298683

4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730-737. PMID: 9212098. [Foundational CSC paper]

5. Dang CV. Links between metabolism and cancer. Genes Dev. 2012;26(9):877-890. PMID: 22549953

6. Pascale RM, et al. Metformin and cancer: Is the evidence strong enough? Eur J Cancer. 2021;145:198-208. PMID: 33395624

7. Carr AC, Vissers MCM. Synthetic or food-derived vitamin C — are they equally bioavailable? Nutrients. 2013;5(11):4284-4304. PMID: 24169506. [IVC mechanistic review]

8. Duan JX, et al. Mitochondria as a novel target for cancer therapy. Future Med Chem. 2010;2(8):1309-1322. PMID: 21426208

9. Lamb R, et al. Antibiotics that target mitochondria effectively eradicate cancer stem cells across cell line types. Oncotarget. 2015;6(7):4569-4584. PMID: 25625193. [Doxycycline / CSC paper]

10. Aggarwal BB, et al. Curcumin: The Indian solid gold. Adv Exp Med Biol. 2007;595:1-75. PMID: 17569205

About the Author

Dr. Yoon Hang "John" Kim, MD, MPH, is a board-certified physician with over 20 years of experience in Preventive Medicine and Integrative & Functional Medicine. He completed a residential fellowship under Dr. Andrew Weil at the University of Arizona and holds additional certifications in Medical Acupuncture (UCLA) and Integrative/Holistic Medicine. He is an IFM Scholar and the author of 3 books and over 20 articles, primarily focused on LDN therapy and integrative approaches to chronic disease.

Dr. Kim specializes in Low Dose Naltrexone (LDN), autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, MCAS, and mold toxicity. He is the founder and moderator of the LDN Support Group (9,000+ members) and leads the Skool community backup at www.skool.com/ldnsupportgroup.

Professional site: www.yoonhangkim.com | Clinical practice: www.directintegrativecare.com